feed,title,long_url,short_url
Benzinga,Evaxion Biotech Says Personalized Cancer Immunotherapy Meets Primary Endpoint In Melanoma Patients,https://benzinga.com/general/biotech/23/04/31864308/evaxion-biotech-says-personalized-cancer-immunotherapy-meets-primary-endpoint-in-melanoma-patient,https://da.gd/WYXRJ
Benzinga,"Brookfield Asset Management Is Fully Priced, Industry Fundamentals Shaky: Analyst Downgrades Stock",https://benzinga.com/analyst-ratings/analyst-color/23/04/31865426/brookfield-asset-management-is-fully-priced-industry-fundamentals-shaky-analyst-dow,https://da.gd/xQ75
